Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | STM-416 |
Synonyms | |
Therapy Description |
STM-416 is an injectable hydrogel formulation of resiquimod, a TLR7/8 agonist, which potentially enhances antitumor immune response and induces tumor cell lysis (PMID: 39735340, NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
STM-416 | STM 416|STM416 | TLR7 Agonist 13 TLR8 Agonist 10 | STM-416 is an injectable hydrogel formulation of resiquimod, a TLR7/8 agonist, which potentially enhances antitumor immune response and induces tumor cell lysis (PMID: 39735340, NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05710848 | Phase Ib/II | STM-416 | A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer | Recruiting | USA | 0 |